|
5. Traitements
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
|
Sanofi Pays to Get Back Into Oncology [In the Pipeline]
|
|
|
|
|
|
This
deal does emphasize how much the company felt that their internal
R&D had come up short. They let a lot of people go, took a lot of
loss on the whole effort, and now they're reaching in for at least
another billion dollars more. . .
|
|
|
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
Merck Strengthens Immuno-oncology Pipeline with cCAM Biotherapeutics Acquisition [GEN]
|
|
|
|
|
|
The
acquisition provides Merck with several early immunotherapy candidates,
including cCAM Biotherapeutics’ lead pipeline candidate, CM-24. The
monoclonal antibody, which targets the immune checkpoint protein
CEACAM1, is currently being evaluated in a Phase I study for the
treatment of advanced or recurrent malignancies, including melanoma,
non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
Study: Firms “underinvest” in long-term cancer research [MIT News]
|
|
|
|
|
|
Specifically,
drugs to treat late-stage cancers are less costly to develop than drugs
for earlier-stage cancers, partly because the late-stage drugs extend
people’s lives for shorter durations of time. This means that the
clinical trials for such drugs get wrapped up more quickly, too — and
provide drug manufacturers more time to control patented drugs in the
marketplace.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
|
|
Does the FDA Reject Anything Any More? [In the Pipeline]
|
|
|
|
|
|
There’s
another possibility, that a number of not-great-but-not-unapprovable
things are getting through – incremental advances. You hear that sort of
description and you think “me-too drugs”, but that’s not necessarily
the case.
|
|
|
|
|
|
|
The FDA Is Basically Approving Everything. Here's The Data To Prove It [Forbes]
|
|
|
|
|
|
The
FDA doesn’t follow the tone set by the President or the party in power,
because the FDA is never the center of anybody’s agenda. Instead, its
tendency, even if its unconscious, is to protect itself against attacks
from the opposing party. A lame duck Democrat and a Republican Congress?
You’re going to get an easy FDA. If a Republican wins the White House
next year, think about selling your drug stocks.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
The Times They Are a Changin’ – And So is FDA [FDA Voice]
|
|
|
|
|
|
FDA
continues to keep pace with new science and technology, found in a
growing number of medical product applications submitted for our review.
For example, applications involving 3-D printing, devices incorporating
nanotechnology and wireless controls, targeted drug therapies, and next
generation sequencing technology are now commonplace in our regulatory
portfolio.
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
|
|
|